Next Article in Journal
The Role of Hydrogen Peroxide in Redox-Dependent Signaling: Homeostatic and Pathological Responses in Mammalian Cells
Next Article in Special Issue
Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation
Previous Article in Journal
The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis
Previous Article in Special Issue
Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site
Review

Allogeneic CAR-T Cells: More than Ease of Access?

1
Department of Haematological Medicine, King’s College London, London SE5 9NU, UK
2
Department of Haematology, King’s College Hospital NHS Foundation Trust, London SE5 9RS, UK
3
Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Sussex, Falmer BN1 9PX, UK
*
Authors to whom correspondence should be addressed.
Cells 2018, 7(10), 155; https://doi.org/10.3390/cells7100155
Received: 10 September 2018 / Revised: 27 September 2018 / Accepted: 27 September 2018 / Published: 1 October 2018
(This article belongs to the Special Issue Emerging Cellular Therapies: T Cells and Beyond)
Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient’s own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several groups have recently described differences in CAR-T cells generated from chronic lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. They may also provide a more functional, potent product for malignancies such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process. Here we review the potential benefits and obstacles for healthy donor, allogeneic CAR-T cells. View Full-Text
Keywords: CAR-T cells; cancer immunotherapy; gene editing CAR-T cells; cancer immunotherapy; gene editing
Show Figures

Figure 1

MDPI and ACS Style

Graham, C.; Jozwik, A.; Pepper, A.; Benjamin, R. Allogeneic CAR-T Cells: More than Ease of Access? Cells 2018, 7, 155. https://doi.org/10.3390/cells7100155

AMA Style

Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T Cells: More than Ease of Access? Cells. 2018; 7(10):155. https://doi.org/10.3390/cells7100155

Chicago/Turabian Style

Graham, Charlotte, Agnieszka Jozwik, Andrea Pepper, and Reuben Benjamin. 2018. "Allogeneic CAR-T Cells: More than Ease of Access?" Cells 7, no. 10: 155. https://doi.org/10.3390/cells7100155

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop